P521: Correlation of histological assessment of mucosal healing with long-term clinical and patient-reported outcomes in patients with moderately to severely active ulcerative colitis treated with upadacitinib: results from the Phase 3 U-ACHIEVE maintenance trialECCO'22Year: 2022
Authors: Parkes, G.(1);Ungaro, R.(2);Danese, S.(3);Abreu, M.(4);Arenson, E.(5);Zhou, W.(6);Ilo, D.(6);Laroux, F.S.(7);Deng, H.(8);Sanchez Gonzalez, Y.(6);Peyrin-Biroulet, L.(9);
(1)Barts Health NHS Trust- Barts and the London School of Medicine and Dentistry, n/a, London, United Kingdom;(2)Icahn School of Medicine at Mount Sinai, Division of Gastroenterology, New York, United States;(3)Gastroenterology and Endoscopy IRCCS Ospedale San Raffaele and University Vita-Salute San Raffaele, n/a, Milano, Italy;(4)Division of Gastroenterology- Crohn's and Colitis Center- University of Miami Miller School of Medicine, n/a, Miami, United States;(5)Adelphi Values, n/a, Boston, United States;(6)AbbVie Inc., n/a, North Chicago, United States;(7)AbbVie Bioresearch Center, n/a, Worcester, United States;(8)AbbVie Inc. and Department of Pharmacy Systems Outcomes and Policy- University of Illinois at Chicago, n/a, Chicago, United States;(9)University Hospital of Nancy- Lorraine University, n/a, Vandoeuvre, France;
P522: Upadacitinib Promotes Histologic and Endoscopic Mucosal Healing: Results from the Upadacitinib Ulcerative Colitis Phase 3 ProgramECCO'22Year: 2022
Authors: Peyrin-Biroulet, L.(1);Siegel, C.(2);Tanida, S.(3);Bossuyt, P.(4);Torres, E.(5);Dubinsky, M.(6);Baert, F.(7);Zhou, W.(8);Klaff, J.(8);Berg, S.(8);Laroux, F.S.(9);Sanchez Gonzalez, Y.(8);Yao, X.(8);Zhou, Q.(8);Reinisch, W.(10);
(1)University Hospital of Nancy, none, Vandoeuvre, France;(2)Dartmouth-Hitchcock Medical Center, none, Lebanon, United States;(3)Naogoya City University Hospital, none, Nagoya, Japan;(4)Imelda General Hospital, none, Bonheiden, Belgium;(5)University of Puerto Rico School of Medicine, none, San Juan, United States;(6)Icahn School of Medicine at Mt Sinai, none, New York City, United States;(7)AZ Delta, none, Roeselare-Menen, Belgium;(8)AbbVie- Inc, none, North Chicago, United States;(9)AbbVie Bioresearch Center, none, Worcester, United States;(10)Medical University of Vienna, none, Vienna, Austria;
P523: effectiveness of biological treatments for inflammatory bowel disease in the elderly patientsECCO'22Year: 2022
Authors: Suarez Ferrer, C.J.(1);Mesonero, F.(2);Caballol, B.(3);Ballester, M.P.(4);Baston Rey, I.(5);Castaño Garcia, A.(6);Miranda Bautista, J.(7);Saiz Chumillas, R.(8);Benitez, J.M.(9);Sanchez Delgado, L.(10);Lopez-Garcia, A.(11);Rubin de Celix, C.(12);Martin-Arranz, M.D.(13);Lopez Sanroman, A.(2);Fernandez-Clotet, A.(3);Merino Murgui, V.(14);Calviño Suarez, C.(5);Florez, P.(6);Lobato Matilla, M.E.(7);Sicilia, B.(8);Soto Escribano, P.(15);Maroto Martin, C.(10);Alonso Abreu, I.(16);Melcarne, L.(17);Elena , P.G.(18);Iyo, E.(19);Elosua Gonzalez, A.(20);Saiz, E.(21);Hernandez Villalba, L.(22);Perez Galindo, P.(23);Torrealba Medina , L.(24);Monsalve Alonso , S.(25);Olmos Jerez, J.A.(26);Dueñas Sadornil , C.(27);Barreiro-De Acosta, M.(5);
(1)Hospital Universitario La Paz, Gastroenterology Department. IBD Unit, Madrid, Spain;(2)Ramón y Cajal University Hospital, Gastroenterology, Madrid, Spain;(3)Hospital Clinic Barcelona, Gastroenterology, Barcelona, Spain;(4)Hospital Clinico de Valencia, gastroenterology, Valencia, Spain;(5)Hospital Universitario Clínico de Santiago, gastroenterology, Santiago de Compostela, Spain;(6)Hospital Universitario Central de Asturias, gastroenterology, Oviedo, Spain;(7)Hospital Universitario Gregorio Marañon, gastroenterology, Madrid, Spain;(8)Burgos University Hospital-, gastroenterology, Burgos, Spain;(9)Hospital Reina Sofia, gastroenterology, Cordoba, Spain;(10)Hospital Universitario de Valladolid-, gastroenterology, Valladolid, Spain;(11)Hospital del Mar, gastroenterology, Barcelona, Spain;(12)Hospital Universitario de La Princesa- Instituto de Investigación Sanitaria Princesa IISIP., gastroenterology, Madrid, Spain;(13)Gastroenterology Department. School of Medicine. Universidad Autónoma de Madrid. Hospital La Paz Institute forHealth Research- La Paz Hospital, Gastroenterology Department. School of Medicine. Universidad Autónoma de Madrid. Hospital La Paz Institute forHealth Research- La Paz Hospital, Madrid, Spain;(14)Hospital Clinico of Valencia, gastroenterology, Valencia, Spain;(15)Hospital Universitario Reina Sofia, gastroenterology, Cordoba, Spain;(16)Hospital Universitario de Canarias., gastroenterology, Tenerife, Spain;(17)Hospital Universitari Parc Taulli- Sabadel-, gastroenterology, Barcelona, Spain;(18)Hospital Royo Villanova-Zaragoza, Gastroenterology, Zaragoza, Spain;(19)Hospital Comarcal de Inca, Gastroenterology Department-, Baleares, Spain;(20)Hospital Garcia Orcoyen, Gastroenterology Department-, Navarra, Spain;(21)Hospital Xara Assistencial Althaia, Gastroenterology, Manresa, Spain;(22)Hospital Santos Reyes-, Gastroenterology Department-, Aranda de Duero, Spain;(23)Pontevedra University Hospital Complex, Gastroenterology Department-, Pontevedra, Spain;(24)Hospital Universitari de Girona Doctor Josep Trueta, gastroenterology, Girona, Spain;(25)Hospital Infanta Elena de Valdemoro, gastroenterology, Madrid, Spain;(26)Hospital Rey Juan Carlos de Móstoles, gastroenterology, Madrid, Spain;(27)Hospital Universitario de Caceres, gastroenterology, Caceres, Spain;on behalf of the Young Group of GETECCU
P524: Compared efficacy of ustekinumab and anti-TNF agents as first-line biological therapy in luminal Crohn's disease.ECCO'22Year: 2022
Authors: Riviere, P.(1);Kanters, C.(2);Ni, A.(2);Pellet, G.(1);Hupe, M.(1);Aboulhamid, N.(2);Poullenot, F.(1);Bitton, A.(2);Zerbib, F.(1);Lakatos, P.(2);Afif, W.(2);Laharie, D.(1);Bessissow, T.(2);
(1)Bordeaux University Hospital, Gastroenterology unit, Pessac, France;(2)McGill University Health Centre, Gastroenterology, Montréal, Canada;
P525: A prospective interventional study to evaluate the effect of hypoxia on healthy volunteers and patients with inflammatory bowel disease: The altitude IBD studyECCO'22Year: 2022
Authors: Vavricka, S.(1);Zeitz, J.(2);Madanchi, M.(1);Biedermann, L.(1);Morsy, Y.(1);Scharl, M.(1);Gassmann, M.(3);Lutz, T.(3);Kunz, A.(4);Bron, D.(4);Rogler, G.(1);Greuter, T.(1);
(1)University Hospital Zurich, Gastroenterology and Hepatology, Zurich, Switzerland;(2)Clinic Hirslanden Zurich, Center of Gastroenterology, Zurich, Switzerland;(3)University of Zurich, Institute of Veterinary Physiology- Vetsuisse Faculty, Zurich, Switzerland;(4)Swiss Aeromedical Center, Swiss Aeromedical Center, Dubendorf, Switzerland;
P526: Measurement of thiopurine metabolites concentrations after one week of treatment does not predict treatment failure in Inflammatory Bowel Disease patientsECCO'22Year: 2022
Authors: DebenMSc, D.(1);Van Moorsel, F.(2,3);Creemers, R.(4,5);Winkens, B.(6);Bus, P.(7);Pierik, M.(5);Simsek, M.(8);De Boer, N.(8);Wong, D.(1);Van Bodegraven, A.(4,8);
(1)Zuyderland MC, Dept. of Clinical Pharmacy- Clinical pharmacology and Toxicology, Sittard-Geleen, The Netherlands;(2)Jeroen Bosch Hospital, Dept. of Pharmacy, 's-Hertogenbosch, The Netherlands;(3)Bernhoven Hospital, Dept. of Clinical Pharmacy, Uden, The Netherlands;(4)Zuyderland MC, Dept. of Gastroenterology- Geriatrics- Internal and Intensive Care Medicine Co-MIK, Sittard-Geleen, The Netherlands;(5)Maastricht University Medical Center, Dev. of Gastroenterology and Hepatology, Maastricht, The Netherlands;(6)Maastricht University Medical Center, Dept. of methodology and statistics, Maastricht, The Netherlands;(7)Laurentius Hospital, Dept. of Gastroenterology and Hepatology, Roermond, The Netherlands;(8)Amsterdam University Medical Center, Dept. of Gastroenterology and Hepatology, Amsterdam, The Netherlands;
P527: Telemedicine in IBD patients: results of a national survey of the Italian IBD patients’ association (AMICI Onlus)ECCO'22Year: 2022
Authors: Costantino, A.(1,2);Caprioli, F.(1,2);Vecchi, M.(1,2);Stocco, D.(3);Aloi, M.(4);Armuzzi, A.(5);Ficari, F.(6);Manguso, F.(7);Mocci, G.(8);Orlando, A.(9); Pironi, L.(10);Radice, S.(11);Rizzello, F.(12);Tongiorgi, A.(13);Leone, S.(14);Bossa, F.(15);
(1)IRCCS Ca’ Granda Ospedale Maggiore Policlinico Foundation, Gastroenterology and Endoscopy Unit, Milan, Italy;(2)University of Milan, Department of Pathophysiology and Transplantation- Milan- Italy, Milan, Italy;(3)Politecnico di Milano, Department of Mathematics, Milan, Italy;(4)Sapienza University of Rome, Department of Pediatrics, Rome, Italy;(5)Fondazione Policlinico Universitario A. Gemelli IRCCS, Internal Medicine and Gastroenterology, Rome, Italy;(6)AUO Careggi, Dipartimento di Medicina Sperimentale Clinica Chirurgia Generale, Florence, Italy;(7)AO Cardarelli, Surgical Department, Naples, Italy;(8)Azienda Ospedaliera ARNAS G. Brotzu-, Gastroenterology, Cagliari, Italy;(9)Villa Sofia-Cervello Hospital, IBD Unit, Palermo, Italy;(10)Policlinico Sant’Orsola Malpighi, Centro IICB- Scienze Mediche, Bologna, Italy;(11)Humanitas Research Hospital, IBD Unit, Milan, Italy;(12)Policlinico Sant’Orsola Malpighi, Department of Internal Medicine and Gastroenterology, Bologna, Italy;(13)Azienda Ospedaliera Pisa, UO Gastroenterologia, Pisa, Italy;(14)Associazione Nazionale per le Malattie Infiammatorie Croniche dell'Intestino, AMICI Onlus, Milan, Italy;(15)Fondazione Casa Sollievo della Sofferenza, Gastroenterologia ed Endoscopia Digestiva, San Giovanni Rotondo, Italy;
P528: Feasibility, satisfaction and machine learning analysis of factors influencing IBD patients’ trust in the mobile application Care4today IBDECCO'22Year: 2022
Authors: Costantino, A.(1,2);Vecchi, M.(1,2);Stocco, D.(3);Noviello, D.(4);Conforti, F.S.(1);Maregatti, M.(4);Caprioli, F.(1,2);
(1)IRCCS Ca’ Granda Ospedale Maggiore Policlinico Foundation, Gastroenterology and Endoscopy Unit, Milan, Italy;(2)University of Milan, Department of Pathophysiology and Transplantation, Milan, Italy;(3)Politecnico di Milano, Department of Mathematics, Milan, Italy;(4)University of Milan, Gastroenterology, Milan, Italy;
P529: Evolution of COVID19 serology in a real-life population of IMID patients. Results of the BELCOMID study: BELgian Cohort study of COVID-19 in Immune Mediated Inflammatory Diseases (IMID).ECCO'22Year: 2022
Authors: Geldof, J.(1);Sabino, J.(2);Ferrante, M.(2);Lambert, J.(3);Lapeere, H.(3);Hillary, T.(4);Van Laethem, A.(4);De Vlam, K.(5);Verschueren, P.(5);Lobaton, T.(1);Vermeire, S.(2);
(1)University Hospital Ghent, Department of Gastroenterology and Hepatology, Ghent, Belgium;(2)University Hospitals Leuven, Department of Gastroenterology and Hepatology, Leuven, Belgium;(3)University Hospital Ghent, Department of Dermatology, Ghent, Belgium;(4)University Hospitals Leuven, Department of Dermatology, Leuven, Belgium;(5)University Hospitals Leuven, Department of Rheumatology, Leuven, Belgium;Studygroup: BELCOMID - BELCOMID studygroup received research grants from following pharmaceutical companies: Almirall Roche Janssen Pfizer Eli Lilly Amgen Biogen Mylan Leo Pharma.
P530: Vedolizumab as the first line of biologic therapy for ulcerative colitis and Crohn’s disease - a systematic review with meta-analysisECCO'22Year: 2022
Authors: Attauabi, M.(1,2,3);Madsen, G.R.(1,2);Bendtsen, F.(1,2);Seidelin, J.B.(3);Burisch, J.(2);
(1)Copenhagen University Hospital- Hvidovre, Gastrounit- Medical Section, Hvidovre, Denmark;(2)University of Copenhagen- Hvidovre Hospital, Copenhagen Center for Inflammatory Bowel Disease in Children- Adolescents and Adults, Hvidovre, Denmark;(3)Herlev Hospital- University of Copenhagen, Department of Gastroenterology and Hepatology, Herlev, Denmark;
P531: Stringent screening strategy significantly reduces reactivation rate of Tuberculosis in Patients with Inflammatory Bowel Disease on anti-TNF therapy in a TB endemic regionECCO'22Year: 2022
Authors: Kumar, P.(1);Vuyyuru, S.K.(1);Kante, B.(1);Sahu, P.(1);Goyal, S.(1);Madhu, D.(1);Jain, S.(1);Ranjan, M.K.(1);Mundhra, S.(1);Golla, R.(1);Singh, M.(1);Virmani, S.(1);Gupta, A.(1);Yadav, N.(1);Kalaivani, M.(1);Sharma , R.(1);Das, P.(1);Makharia, G.(1);Kedia, S.(1);Ahuja, V.(1);
(1)All India Institute of Medical Sciences, Department of Gastroenterology and Human Nutrition, New Delhi, India;
P532: Proactive therapeutic drug monitoring improves clinical outcomes in patients with inadequate post-induction infliximab trough levelsECCO'22Year: 2022
Authors: Botto, I.(1);Coelho Rodrigues, I.(1);Serrazina, J.(1);Fernandes, S.(1);Bernardo, S.(1);Gonçalves, A.R.(1);Moura Santos, P.(1);Valente, A.(1);Correia, L.(1);Tato Marinho, R.(1);
(1)Centro Hospitalar Universitário Lisboa Norte, Serviço de Gastrenterologia, Lisbon, Portugal;
P533: Predictors of sustained remission after infliximab de-escalation in patients with inflammatory bowel diseasesECCO'22Year: 2022
Authors: Kantasiripitak, W.(1);Outtier, A.(2,3);Thomas, D.(1);Sabino, J.(2,3);Vermeire, S.(2,3);Ferrante, M.(2,3);Dreesen, E.(1);
(1)University of Leuven, Department of Pharmaceutical and Pharmacological Sciences, Leuven, Belgium;(2)University Hospitals Leuven, Department of Gastroenterology and Hepatology, Leuven, Belgium;(3)University of Leuven, Department of Chronic Diseases and Metabolism, Leuven, Belgium;
P534: Effectiveness and safety of Adalimumab switch from originator to biosimilar in patients with inflammatory bowel disease in clinical remissionECCO'22Year: 2022
Authors: Gros , B.(1);Soto Escribano , P.(1);Marín Pedrosa , S.(1);Medina Medina , R.(2);Benítez , J.M.(1);Iglesias-Flores , E.(1);
(1)Reina Sofía University Hospital, Department of Gastroenterology, Córdoba, Spain;(2)Maimónides Biomedical Research Institute IMIBIC, Gastroenterology, Córdoba, Spain;
P535: Association of anti-Infliximab antibodies and HLADQA1*05 variant in ulcerative colitis : a retrospective single centre studyECCO'22Year: 2022
Authors: Aleman Gonzalez, H.(1);Sankaranarayanan, R.(1);Pattinson, A.(1);Turnbull, J.(1);Katie, S.(1);Whitehead, E.(1);Talbot, A.(1);Myers, S.(1);Sebastian, S.(1);
(1)Hull University Teaching Hospitals, Inflammatory Bowel Disease, Kingston Upon Hull, United Kingdom;
P536: Comparison of outcomes of infliximab biosimilar CT-P13 with infliximab originator in patients with inflammatory bowel diseaseECCO'22Year: 2022
Authors: Yüksel, I.(1,2);Baspınar, B.(1);Durak, M.B.(1);Kilic, V.(1);Kivrakoglu, F.(1,2);Guven, I.E.(1);Kosar, K.(1);Erdogan, C.(1);Alkan, A.(3);
(1)Ankara City Hospital, Gastroenterology, Ankara, Turkey;(2)Ankara Yildirim Beyazit University School of Medicine, Gastroenterology, Ankara, Turkey;(3)Ankara Yildirim Beyazit University School of Medicine, Biostatistics and Medical Informatics, Ankara, Turkey;
P537: Steroid use in patients with immune checkpoint inhibitor colitisECCO'22Year: 2022
Authors: Crothers-Stomps, L.(1);Mohsen, W.(1);Kakkadasam Ramaswamy, P.(1);Mason, R.(2);Dzienis, M.(2);Edwards, J.(1);
(1)Gold Coast University Hospital, Gastroenterology, Gold Coast, Australia;(2)Gold Coast University Hospital, Oncology, Gold Coast, Australia;
P539: COVID-19 is Associated with Long-term Elevated Fecal Calprotectin Levels in Patients with Crohn's Disease but not in Ulcerative Colitis.ECCO'22Year: 2022
Authors: Shafrir, A.(1,2);Benson, A.A.(1);Zinger, A.(1);Shauli Aharonov, M.(3);Katz, L.H.(1);
(1)Hadassah Medical Center, Department of Gastroenterology and Hepatology, Jerusalem, Israel;(2)Meuhedet Health Maintenace Organization, Jerusalem District, Tel Aviv, Israel;(3)Jerusalem College of Technology, Department of Industry and management, Jerusalem, Israel;
P540: Longitudinal Dynamics of Gut Microbiome and Metabolome After Biological Therapy in Inflammatory Bowel DiseasesECCO'22Year: 2022
Authors: Ahmed, M.(1);Metwaly, A.(1);Hammoudi, N.(2);Meng, C.(3);Köhler, N.(4);Le Bourhis, L.(2);Pauling, J.(4);Kleigrewe, K.(3);Allez, M.(2);Haller, D.(1);
(1)Technical University Munich, Chair of Nutrition and Immunology, Freising, Germany;(2)APHP- Hôpital Saint Louis- INSERM UMRS 1160- Paris Diderot- Sorbonne Paris-Cité University- Paris- France, Department of Gastroenterology, Paris, France;(3)Technical University of Munich, Bavarian Center for Biomolecular Mass Spectrometry BayBioMS, Freising, Germany;(4)Technical University of Munich, LipiTUM- Chair of Experimental Bioinformatics, Freising, Germany;
